Ankr Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI that virtualizes clinic front desk, medical assistant, and scribe functions for on-demand virtual clinics; YC-backed at $2.3M revenue with EHR integration generating $1M new revenue for average clinic.
About
Ankr Health is a San Francisco-based healthcare technology company using generative AI to virtualize clinic infrastructure — automating front desk operations, medical assistant workflows, and clinical documentation (AI scribe functions) that enable physicians to launch on-demand virtual and hybrid clinics without the full overhead of physical clinic staff. Founded in 2022 and backed by Y Combinator with $500,000 raised from MedTech Innovator, WorldQuant Ventures, and YC, Ankr Health generated $2.3 million in revenue in 2024 with a 15-person team, with integration across all major EHR systems (Epic, Cerner, athenahealth) and a reported $1 million in new annual revenue generated for average clinic customers.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.